Opportunities and Challenges in the Development of Genomic Technologies
DOI:
Abstract
Genomic technologies have made rapid progress in modern medicine, providing a deeper understanding of the genetic factors that influence health and disease. In Turkey, these technologies have significant potential to transform medical diagnostics, address genetic disorders, and contribute to personalized therapies. This study explores the development, impact, and challenges of genomic technologies in the Turkish healthcare system through a descriptive case study approach. Document analysis and semi-structured interviews with 20 experts, including researchers, healthcare practitioners, and policymakers, were conducted. The findings indicate Turkey’s growing commitment to genomic research, with increased funding allocations and modern facilities. Genomic technologies have significantly improved diagnostic accuracy for genetic disorders and cancer, particularly through Next-Generation Sequencing (NGS) and genomic profiling. However, challenges such as limited funding (only 10% of the healthcare budget), shortage of skilled personnel, and regulatory gaps persist. Despite these barriers, Turkey shows strong potential to become a leader in genomic research. Recommendations for future research include addressing these challenges through increased investment, public awareness campaigns, and workforce development. By overcoming these obstacles, Türkiye can successfully integrate genomic technologies into its healthcare system, improving medical care and promoting personalized treatment
Downloads
Views : 325
Downloads : 252
References
F. C. Udegbe, et al., “Precision Medicine and Genomics: A comprehensive review of IT-enabled approaches,” International Medical Science Research Journal, vol. 4, no. 4, pp. 509–520, 2024.
G. Christyani, M. Carswell, S. Qin, and W. Kim, “An overview of advances in rare cancer diagnosis and treatment,” International Journal of Molecular Sciences, vol. 25, no. 2, 2024.
R. D. McMullan, R. Urwin, M. Wiggins, et al., “Are two-person checks more effective than one-person checks for safety-critical tasks in high-consequence industries outside of healthcare? A systematic review,” Applied Ergonomics, 2023.
S. B. Junaid, A. A. Imam, A. O. Balogun, L. C. De Silva, Y. A. Surakat, G. Kumar, M. Abdulkarim, A. N. Shuaibu, A. Garba, Y. Sahalu, A. Mohammed, T. Y. Mohammed, B. A. Abdulkadir, A. A. Abba, N. A. I. Kakumi, and S. Mahamad, “Recent advancements in emerging technologies for healthcare management systems: A survey,” Healthcare (Basel), vol. 10, no. 10, 2022.
D. D. Dolan, S. S. Lee, and M. K. Cho, “Three decades of ethical, legal, and social implications research: Looking back to chart a path forward,” Cell Genomics, vol. 2, no. 7, 2022.
A. K. Smit, A. Gokoolparsadh, R. McWhirter, L. Newett, V. Milch, A. Hermes, A. McInerney-Leo, and A. J. Newson, “Ethical, legal, and social issues related to genetics and genomics in cancer: A scoping review and narrative synthesis,” Genetics in Medicine, vol. 26, no. 12, 2024.
H. Satam, K. Joshi, U. Mangrolia, S. Waghoo, G. Zaidi, S. Rawool, R. P. Thakare, S. Banday, A. K. Mishra, G. Das, and S. K. Malonia, “Next-generation sequencing technology: Current trends and advancements,” Biology (Basel), vol. 12, no. 7, 2023.
C. Guo, X. Ma, F. Gao, and Y. Guo, “Off-target effects in CRISPR/Cas9 gene editing,” Front. Bioeng. Biotechnol., vol. 11, Art. no. 1143157, Mar. 2023.
J. P. J. Merlin and H. Abrahamse, “Optimizing CRISPR/Cas9 precision: Mitigating off-target effects for safe integration with photodynamic and stem cell therapies in cancer treatment,” Biomed. Pharmacother., vol. 180, 2024.
H. Ura, S. Togi, and Y. Niida, “A comparison of mRNA sequencing (RNA-Seq) library preparation methods for transcriptome analysis,” BMC Genomics, vol. 23, 2022.
M. H. Albujja, M. Al-Ghedan, L. Dakshnamoorthy, and J. Pla Victori, “Preimplantation genetic testing for embryos predisposed to hereditary cancer: Possibilities and challenges,” Cancer Pathog. Ther., vol. 2, no. 1, pp. 1-14, May 16, 2023.
S. M. Swain, M. Shastry, and E. Hamilton, “Targeting HER2-positive breast cancer: advances and future directions,” Nat. Rev. Drug Discov., vol. 22, no. 2, pp. 101-126, Feb. 2023.
J. Su, L. Yang, Z. Sun, and X. Zhan, “Personalized drug therapy: Innovative concept guided with proteoformics,” Mol. Cell Proteomics, vol. 23, no. 3, 2024.
K. K. Adhit, A. Wanjari, S. Menon, and K. S., “Liquid biopsy: An evolving paradigm for non-invasive disease diagnosis and monitoring in medicine,” Cureus, vol. 15, no. 12, 2023.
N. D. Kolanu, “CRISPR-Cas9 gene editing: Curing genetic diseases by inherited epigenetic modifications,” Glob. Med. Genet., vol. 11, no. 1, pp. 113-122, Mar. 2024.
A. M. Gutierrez et al., “Examining access to care in clinical genomic research and medicine: Experiences from the CSER Consortium,” J. Clin. Transl. Sci., vol. 5, no. 1, 2021.
Y. Wang, Y. He, Y. Shi, D. C. Qian, K. J. Gray, R. Winn, and A. R. Martin, “Aspiring toward equitable benefits from genomic advances to individuals of ancestrally diverse backgrounds,” Am. J. Hum. Genet., vol. 111, no. 5, pp. 809-824, 2024.
T. Astronautas, “The impact of technology on personalized care for patients,” Tres Astronautas, Oct. 2023. [Online]. Available: https://www.tresastronautas.com/en/blog/the-impact-of-techno logy-on-personalized-care-for-patients. [Accessed: Aug. 6, 2024].
H. Ateia, P. Ogrodzki, H. V. Wilson, S. Ganesan, R. Halwani, A. Koshy, and W. A. Zaher, “Population Genome Programs across the Middle East and North Africa: Successes, Challenges, and Future Directions,” Biomed Hub, vol. 8, no. 1, pp. 60–71, 2023.
Z. Wang, B. Gregg, and L. Du, “Regulatory barriers to US-China collaboration for generative AI development in genomic research,” Cell Genomics, vol. 4, no. 6, 2024.
M. Javaid, A. Haleem, and R. P. Singh, “Health informatics to enhance the healthcare industry's culture: An extensive analysis of its features, contributions, applications and limitations,” Informatics and Health, vol. 1, no. 2, pp. 123–148, 2024.
M. Yousif, S. Asghar, J. Akbar, et al., “Exploring the perspectives of healthcare professionals regarding artificial intelligence; acceptance and challenges,” BMC Health Serv. Res., vol. 24, no. 1200, 2024.
A. S. Şık, A. U. Aydınoğlu, and Y. A. Son, “Assessing the readiness of Turkish health information systems for integrating genetic/genomic patient data: System architecture and available terminologies, legislative, and protection of personal data,” Health Policy, vol. 125, no. 2, pp. 203–212, 2021.
A. S. Pillai, “Artificial Intelligence in healthcare systems of low- and middle-income countries: requirements, gaps, challenges, and potential strategies,” Int. J. Appl. Health Care Analytics, vol. 8, no. 3, pp. 19–33, 2023.
G. A. Alarcón Garavito, T. Moniz, N. Déom, et al., “The implementation of large-scale genomic screening or diagnostic programmes: A rapid evidence review,” Eur. J. Hum. Genet., vol. 31, pp. 282–295, 2023.
T. Coleman, T. Bensend, R. Mills, L. A. Orlando, and L. Doyle, “Critical components of genomic medicine practice for non-genetics healthcare professionals: Genetic counselors' perspectives and implications for medical education,” J. Genet. Couns., vol. 32, no. 4, pp. 798–811, 2023.
